Quick Answer
Bolt Biotherapeutics, Inc. reported Stockholders Equity of $26.50 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $26.50M | -53.7% |
| 2024 | $57.20M | -49.3% |
| 2023 | $112.74M | -34.3% |
| 2022 | $171.51M | -31.4% |
| 2021 | $250.12M | +338.3% |
| 2020 | -$104.95M | -128.9% |
| 2019 | -$45.85M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.10M | -55.4% | -17.4% |
| June 30, 2025 | $38.84M | -54.8% | -17.0% |
| March 31, 2025 | $46.81M | -55.1% | -18.2% |
| December 31, 2024 | $57.20M | -49.3% | -20.6% |
| September 30, 2024 | $72.03M | -43.8% | -16.1% |
| June 30, 2024 | $85.86M | -39.6% | -17.6% |
| March 31, 2024 | $104.16M | -33.9% | -7.6% |
| December 31, 2023 | $112.74M | -34.3% | -12.1% |
- Bolt Biotherapeutics, Inc. showed a decrease of -53.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Bolt Biotherapeutics, Inc.’s stockholders equity has grown by 157.8% (from -$45.85 million to $26.50 million).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: